Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient. - Wikidata - awgldk - TriplyDB

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

http://www.wikidata.org/entity/Q33801986

about

Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice.Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence.Comparative Incidence of Conformational, Neurodegenerative Disorders.Biochemical and morphological characterization of the AβPP/PS/tau triple transgenic mouse model and its relevance to sporadic Alzheimer's disease.Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders.Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.Is Alzheimer's disease amyloidosis the result of a repair mechanism gone astray?Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.Alzheimer's disease and immunotherapy: what is wrong with clinical trials?Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.

P2860

Q28488690-1B895186-1183-4565-886C-3F686C5377A0 Q33626081-3852311C-29B4-442F-BF3D-4FC4C08B30D1 Q33777535-5E450FAD-EFFC-4DDD-9145-08FE1A15206D Q35240865-4A60D8FE-A364-4C63-9D8F-BB169C0900D7 Q35763399-0259CF89-C0F7-4735-A689-9104214FC48A Q35890955-37EE6E95-838B-4328-AD96-FB8D5B89210D Q36121377-77DB066F-BEB1-403A-9243-AC3FF615BECF Q36424857-94405EC3-7EAB-40D5-B474-10E39FB069D9 Q36575903-A208F1F7-CC75-4142-B993-41B6C3DCD956 Q37053839-B3ADC477-08A6-4B80-A443-D42C07122AAB Q37435886-F00BB090-769E-43C9-BBB0-867B6B1E136C Q37698598-B7BEB0FC-79FF-446D-A75F-349A9687DB64 Q38161675-ED5EFCC2-2179-441A-A1D8-A2DCB5B8E27D Q38176899-BC3FCA5C-ECE6-482C-A428-939946536512 Q38912275-712F65B8-9587-4800-B94D-3F55697A2932 Q51481172-C20222EA-571A-4CE2-9ACA-E54D63F011AE

P2860

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

http://www.wikidata.org/entity/Q33801986

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

@ast

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

@en

type

label

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

@ast

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

@en

prefLabel

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

@ast

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

@en

P1433

Q33801986-30E583E0-990F-4BB7-B0EC-95BE3DBF2268

P1476

Q33801986-4E799F15-3114-4DD5-BF0C-5DB449BD8B02

P2093

Q33801986-099E62D5-79FD-4D58-AB5E-DF9FC3A81A05

Q33801986-122E8260-F0AE-4FA2-B857-BE2939E920EA

Q33801986-4726565E-E2EA-4933-9A7D-E6A2D5C6944B

Q33801986-494A9687-D285-41BA-B602-F9809FCE6AEC

Q33801986-79083AE9-F4C6-44B1-8EE6-FF592A8FECAD

Q33801986-EA0CE93F-BC70-47F3-A440-55EEED0257A4

P2860

Q33801986-06AF36C0-65F8-46DB-8B1F-DFA44BAB8AFB

Q33801986-13901503-085C-4E94-B88F-D369EFF5DA4A

Q33801986-148023EA-5F78-4A41-8D0A-2999E734034D

Q33801986-1B242B6B-C1DA-4230-83E8-ECB43D757115

Q33801986-1E6E1263-EBFC-41F0-B491-4F76875A001D

Q33801986-1F7F9BE2-5CE1-4DA3-8879-C778E785A8D6

Q33801986-271399AC-3A35-45D0-928C-CDF20317EC1F

Q33801986-27E4B866-2B3B-4A36-903D-1E51D25E04EE

Q33801986-32A0C427-8E30-4062-A000-B4A82D9154D6

Q33801986-35F840D7-5B47-4487-8FA2-898BCCE14617

P304

Q33801986-6BB0CEEC-3FD7-4D28-996E-890D6671C68C

P31

Q33801986-34D14EE1-A934-4167-AB92-A30AA95EB655

P356

Q33801986-E02B90BD-6C6D-43DF-A858-617AEB3266A0

P433

Q33801986-54B194CE-55C8-4EBD-8D6F-80C83359C646

P478

Q33801986-EF785DE4-EB1A-4F62-BA8F-1BDAC1BE079F

P50

Q33801986-56BFE3D1-D2B6-483C-8BA6-12AD465CF251

P577

Q33801986-FA6E8869-42A3-4F58-B79D-511602E8E7DA

P5875

Q33801986-6772891D-3CD6-45FB-B985-513607F56C74

P698

Q33801986-24F0D92C-0654-4B35-B39E-AD646F7548E1

P921

Q33801986-742B0757-F6B0-4EA7-8A5C-553B3603FE72

P932

Q33801986-3DADC321-6988-41D2-9EE4-F1AF385140DB

P356

JAD-2011-101809

P1433

Journal of Alzheimer's Disease

P1476

Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.

@en

P2093

Alex E Roher

http://www.w3.org/2001/XMLSchema#string

Chera L Maarouf

http://www.w3.org/2001/XMLSchema#string

Ian D Daugs

http://www.w3.org/2001/XMLSchema#string

Jesse M Hunter

http://www.w3.org/2001/XMLSchema#string

Marwan N Sabbagh

http://www.w3.org/2001/XMLSchema#string

Tyler A Kokjohn

http://www.w3.org/2001/XMLSchema#string

P2860

beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease

Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid -related Behavioral Deficits in a Mouse Model of Alzheimer Disease

Neuropathological stageing of Alzheimer-related changes

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates.

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach.

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques.

Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome

P304

315-325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/JAD-2011-101809

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49781898

http://www.w3.org/2001/XMLSchema#string

P698

21263194

http://www.w3.org/2001/XMLSchema#string

P921

P932

3172868

http://www.w3.org/2001/XMLSchema#string